SLC2A1 and cancer: This transformation involves the degradation of caveolin-1 (CAV1) by activating the ERK1/2 pathway, leading to metabolic switching toward aerobic glycolysis in fibroblasts.301 Additionally, some cancers highly express glucose transporter 1 (GLUT1), and the transfer of secreted GLUT1 through EVs to recipient cells can contribute to metabolic changes in those cells.